{
    "2018-11-23": [
        [
            {
                "time": "2018-04-15",
                "original_text": "FDA Approves Roche Subsidiary's Treatment for Acute Myeloid Leukemia",
                "features": {
                    "keywords": [
                        "FDA",
                        "Approves",
                        "Roche",
                        "Treatment",
                        "Acute Myeloid Leukemia"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-06-20",
                "original_text": "Pharma Stock Roundup: Cancer Approvals for PFE & ABBV, CHMP Nod for Several Drugs",
                "features": {
                    "keywords": [
                        "Pharma",
                        "Stock",
                        "Cancer",
                        "Approvals",
                        "PFE",
                        "ABBV",
                        "CHMP"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-07-10",
                "original_text": "Gauging Analysts’ Views on Tesaro Stock",
                "features": {
                    "keywords": [
                        "Analysts",
                        "Views",
                        "Tesaro",
                        "Stock"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "biotechnology"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-08-05",
                "original_text": "Understanding Tesaro’s Gross Margin Trend",
                "features": {
                    "keywords": [
                        "Understanding",
                        "Tesaro",
                        "Gross",
                        "Margin",
                        "Trend"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "biotechnology"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}